Marker | Sample type | n= | Population | AUC | Confidence interval (95%) | Study |
---|---|---|---|---|---|---|
GHSR | Urine | 74 | Referral | 0.7 | 0.56–0.84 | van den Helder, 2020 |
GHSR | Cervicovaginal swab | 304 | Screening | 0.645 | 0.576–0.714 | de Waard, 2023 |
GHSR | Urine | 33 | Referral | 0.769 | 0.561–0.897 | Van Keer, 2021 |
GHSR | Urine | 245 | Referral | 0.79 | 0.72–0.84 | van den Helder, 2022 |
ST6GALNAC5 | Urine | 33 | Referral | 0.628 | 0.465–0.725 | Van Keer, 2021 |
ST6GALNAC5 | Cervicovaginal swab | 304 | Screening | 0.676 | 0.609–0.627 | de Waard, 2023 |
SST | Urine | 74 | Referral | 0.73 | 0.59–0.86 | van den Helder, 2020 |
SST | Urine | 33 | Referral | 0.634 | 0.473–0.809 | Van Keer, 2021 |
SST | Cervicovaginal swab | 304 | Screening | 0.7 | 0.637–0.764 | de Waard, 2023 |
SST | Urine | 245 | Referral | 0.72 | 0.65–0.79 | van den Helder, 2022 |
ZIC1 | Urine | 74 | Referral | 0.62 | 0.47–0.77 | van den Helder, 2020 |
ZIC1 | Urine | 33 | Referral | 0.558 | 0.400–0.742 | Van Keer, 2021 |
ZIC1 | Urine | 245 | Referral | 0.72 | 0.66–0.78 | van den Helder, 2022 |
ZIC1 | Cervicovaginal swab | 304 | Screening | 0.787 | 0.729–0.863 | de Waard, 2023 |
LHX8 | Urine | 74 | Referral | 0.68 | 0.54–0.82 | van den Helder, 2020 |
LHX8 | Urine | 33 | Referral | 0.682 | 0.465–0.842 | Van Keer, 2021 |
LHX8 | Urine | 245 | Referral | 0.78 | 0.72–0.83 | van den Helder, 2022 |
LHX8 | Cervicovaginal swab | 304 | Screening | 0.781 | 0.721–0.841 | de Waard, 2023 |
ASCL1 | Urine | 74 | Referral | 0.79 | 0.67–0.91 | van den Helder, 2020 |
ASCL1 | Urine | 33 | Referral | 0.566 | 0.473–0.849 | Van Keer, 2021 |
ASCL1 | Cervicovaginal swab | 304 | Screening | 0.806 | 0.749–0.863 | de Waard, 2023 |
ASCL1 | Urine | 245 | Referral | 0.83 | 0.77–0.88 | van den Helder, 2022 |